CORINNE ANGYAL: Open Payments
NPI 1699383612 · DANBURY, CT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,761 in 131 payments from 21 companies in 2025. Trend: 2023 $125 · 2024 $1,290 · 2025 $2,761
Food & beverage: $2,752Education: $10
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 48 | $752 |
| Takeda Pharmaceuticals U.S.A., Inc. | 18 | $479 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 11 | $228 |
| Janssen Biotech, Inc. | 13 | $219 |
| QOL Medical, LLC | 4 | $158 |
| GENZYME CORPORATION | 2 | $156 |
| Ardelyx, Inc. | 6 | $135 |
| Lilly USA, LLC | 6 | $119 |
| Exact Sciences Corporation | 4 | $84 |
| Ferring Pharmaceuticals Inc. | 3 | $62 |
Products named: LINZESS, ENTYVIO, TREMFYA, XIFAXAN, RINVOQ, DUPIXENT, Sucraid, IBSRELA.
Industry payments across CT — which companies pay providers there.
